Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity.

A. Fernández-Carvajal,M. V. Soldovieri,Ilaria Mosca,E. Novellino,A. Ferrer-Montiel,M. Taglialatela,M. Sala,C. Ostacolo,G. Pepe,A. Bertamino,I. Gomez-Monterrey,N. Iraci,P. Ambrosino,Tania Ciaglia,Veronica Di Sarno,P. Campiglia,Sara González-Rodríguez,Simona Musella
DOI: https://doi.org/10.1021/acs.jmedchem.8b00545
IF: 8.039
2018-06-25
Journal of Medicinal Chemistry
Abstract:TRPM8 has been implicated in nociception and pain and is currently regarded as an attractive target for the pharmacological treatment of neuropathic pain syndromes. A series of analogues of N, N'-dibenzyl tryptamine 1, a potent TRPM8 antagonist, was prepared and screened using a fluorescence-based in vitro assay based on menthol-evoked calcium influx in TRPM8 stably transfected HEK293 cells. The tryptophan derivative 14 was identified as a potent (IC50 0.2 ± 0.2 nM) and selective TRPM8 antagonist. In vivo, 14 showed significant target coverage in both an icilin-induced WDS (at 1-30 mg/kg s.c.) and oxaliplatin-induced cold allodynia (at 0.1-1 μg s.c.) mice models. Molecular modeling studies identified the putative binding mode of these antagonists, suggesting that they could influence an interaction network between the S1-4 transmembrane segments and the TRP domains of the channel subunits. The tryptophan moiety provides a new pharmacophoric scaffold for the design of highly potent modulators of TRPM8-mediated pain.
Chemistry,Medicine
What problem does this paper attempt to address?